Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction
- 28 April 2003
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 17 (2), 144-150
- https://doi.org/10.1034/j.1399-0012.2003.00036.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized, International Study of Cyclosporine Microemulsion Absorption Profiling in Renal Transplantation with Basiliximab ImmunoprophylaxisAmerican Journal of Transplantation, 2002
- SAFETY, TOLERABILITY AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL BASED FORMULATION OF CYCLOSPORINE - RESULTS AT SIX MONTHS AFTER TRANSPLANTATION1,2Transplantation, 1999
- PREDICTORS OF LONG-TERM RENAL FUNCTION AFTER HEART TRANSPLANTATIONTransplantation, 1999
- COMPARISON OF NEORAL DOSE MONITORING WITH CYCLOSPORINE TROUGH LEVELS VERSUS 2-HR POSTDOSE LEVELS IN STABLE LIVER TRANSPLANT PATIENTS1,2Transplantation, 1998
- A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1Transplantation, 1998
- CYCLOSPORINE-ASSOCIATED END-STAGE NEPHROPATHY AFTER CARDIAC TRANSPLANTATIONTransplantation, 1997
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.JCI Insight, 1995
- Cyclosporine-Associated Chronic NephropathyNew England Journal of Medicine, 1984
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976